• Department of Respiratory Medicine, West China Hospital, Sichuan University. Chengdu, Sichuan ,610041, China;
Export PDF Favorites Scan Get Citation

抗生素在哮喘當中的應用一直備受爭議。近年的研究主要集中于大環內酯類抗生素(Macrolides)的非抗菌效應,已有研究發現l4元環和l5元環的大環內酯類抗生素具有類激素樣抗炎活性[1]。作為新一代大環內酯類衍生物的泰利霉素(Telithromycin)由于其獨特的抗細菌耐藥性,一問世便受到廣泛關注,而近期公布的TELICAST試驗(The Telithromycin,Chlamydophila,and Asthma Trial)中關于其在哮喘急性加重療效方面的結果更是令人振奮。該試驗發現,對已確診的哮喘急性加重期患者,在指南推薦的常規治療基礎上加用為期10 d的泰利霉素口服(800 mg/d),可使哮喘癥狀評分明顯下降,肺功能指標改善,但其發揮療效的機制尚不十分清楚[2]。

Citation: YAO Rong,LIANG Zongan. The application of macrolides in the treatment of asthma. Chinese Journal of Respiratory and Critical Care Medicine, 2007, 6(5): 326-328. doi: Copy

Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved